Nanna Sulai is an Oncology physician. OpenAlex indexes 19 publications with 1,321 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
910 E Houston St Ste 100
Tyler, TX 757028363
Telephone
903-579-9800Provider last certified this registry record 13 Apr 2022.
Industry payments
47 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20259 payments
- ABBVIE INC.Program year20255 payments
- Tempus AI, IncProgram year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
60%PD-1 inhibitor30.7%Pembrolizumab63%Nivolumab37%Part B, office-administered≥35 patientsMicrotubule Inhibitor12.8%Paclitaxel100%Part B, office-administered≥33 patients+ 8 more classes in this area
Blood & clotting
16%Erythropoiesis-stimulating Agent8.5%Darbepoetin alfa100%Part B, office-administered≥15 patientsParenteral Iron Replacement7.4%Iron sucrose100%Part B, office-administered≥18 patients+ 1 more class in this area
Metabolism & gastrointestinal
12.2%Other antiemetics9%Fosaprepitant100%Part B, office-administered≥29 patientsSerotonin-3 Receptor Antagonist2%Granisetron hydrochloride52%Palonosetron hcl47%Ondansetron Odt2%Part D + Part B≥47 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Journal of Clinical Oncology
2018 - Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma.
Journal of Clinical Oncology
2018 - Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
PubMed
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”